Preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells

Future Oncology

Volumn 9, Issue 8, 2013, Pages 1195-1206

  Hallaj Nezhadi, Somayeh ^a   Valizadeh, Hadi ^a   Baradaran, Behzad ^b   Dobakhti, Faramarz ^c   Lotfipour, Farzaneh ^d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

gelatin; gene delivery; IL 12; nanoparticle; plasmid DNA

Indexed keywords

ALCOHOL; CYTOKINE; GELATIN; GELATIN NANOPARTICLE; INTERLEUKIN 12; NANOPARTICLE; PLASMID DNA; PUMVC3 HIL 12; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; CYTOTOXICITY; DISPERSION; DRUG FORMULATION; DRUG SYNTHESIS; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC TRANSFECTION; MOLECULAR SIZE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; TUMOR CELL LINE; ZETA POTENTIAL;

CARCINOMA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DNA; GELATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INTERLEUKIN-12; NANOPARTICLES;

EID: 84881291050     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.82     Document Type: Article

References (43)

1. Weir B, Zhao X, Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 6 (5), 433-438 (2004).
2. Cortesina G, De Stefani A, Sacchi M, Rosso S, Galeazzi E. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck 15 (3), 266-270 (1993).
3. Kresina TF. An Introduction to Molecular Medicine and Gene Therapy. Kresina TF (Ed.). John Wiley & Sons, Inc., NY, USA, 252-255 (2001).
4. Brunda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178 (4), 1223-1230 (1993).
5. Ma X, Trinchieri G. Regulation of interleukin-12 production in antigen-presenting cells. Adv. Immunol. 79, 55-92 (2001).
6. Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J. Immunol. 156 (3), 1095-1100 (1996).
7. Rodolfo M, Colombo MP. Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 19 (1), 114-120 (1999).
8. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl Acad. Sci. USA 92 (6), 2219-2223 (1995).
9. Car BD, Eng VM, Lipman JM, Anderson TD. The toxicology of interleukin-12: A review. Toxicol. Pathol. 27 (1), 58-63 (1999).
10. Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J. Control. Release 87 (1-3), 177-186 (2003).
11. Tan J, Newton CA, Djeu JY et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 56 (15), 3399-3403 (1996).
12. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: A comprehensive review. AAPS J. 7 (1), E61-E77 (2005).
13. Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers. Int. J. Pharm. 229 (1-2), 1-21 (2001).
14. Kreuter J. Nanoparticles - a historical perspective. Int. J. Pharm. 331 (1), 1-10 (2007).
15. Hallaj-Nezhadi S, Valizadeh H, Dastmalchi S et al. Preparation of chitosan-plasmid DNA nanoparticles encoding interleukin-12 and their expression in CT-26 colon carcinoma cells. J. Pharm. Pharm. Sci. 14 (2), 181-195 (2011).
16. Nezhadi SH, Choong PF, Lotfipour F, Dass CR. Gelatin-based delivery systems for cancer gene therapy. J. Drug Target 17 (10), 731-738 (2009).
17. Digenis GA, Gold TB, Shah VP. Cross-linking of gelatin capsules and its relevance to their in vitro-in vivo performance. J. Pharm. Sci. 83 (7), 915-921 (1994).
18. Truong-Le VL, August JT, Leong KW. Controlled gene delivery by DNA-gelatin nanospheres. Hum. Gene Ther. 9 (12), 1709-1717 (1998).
19. Galaev I, Mattiasson B. Polymeric carriers for regional drug therapy. In: Smart Polymers Applications in Biotechnology and Biomedicine. CRC Press, Taylor & Francis Group, FL, USA, 373 (2008).
20. Cascone MG, Lazzeri L, Carmignani C, Zhu Z. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J. Mater. Sci. Mater. Med. 13 (5), 523-526 (2002).
21. Leong KW, Mao HQ, Truong-Le VL, Roy K, Walsh SM, August JT. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Control Release 53 (1-3), 183-193 (1998).
22. Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin. Drug Deliv. 7 (10), 1191-1207 (2010).
23. Xu X, Capito RM, Spector M. Plasmid size influences chitosan nanoparticle mediated gene transfer to chondrocytes. J. Biomed. Mater. Res. A 84 (4), 1038-1048 (2008).
24. Zhang X, Yu C, Xushi, Zhang C, Tang T, Dai K. Direct chitosan-mediated gene delivery to the rabbit knee joints in vitro and in vivo. Biochem. Biophys. Res. Commun. 341 (1), 202-208 (2006).
25. Yin XL, Wang N, Wei X, Xie GF, Li JJ, Liang HJ. Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice. Cancer Lett. 322 (1), 92-97 (2012).
26. Alonso MJ. Nanomedicines for overcoming biological barriers. Biomed. Pharmacother. 58 (3), 168-172 (2004).
27. Faneca H, Cabrita AS, Simoes S, Pedroso De Lima MC. Evaluation of the antitumoral effect mediated by IL-12 and HSV-tk genes when delivered by a novel lipid-based system. Biochim. Biophys. Acta 1768 (5), 1093-1102 (2007).
28. Speroni L, Gasparri J, De Los ABV et al. Antitumoral effect of IL-12 gene transfected via liposomes into B16F0 cells. Acta Biochim. Pol. 56 (2), 249-253 (2009).
29. Daud AI, Deconti RC, Andrews S et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26 (36), 5896-5903 (2008).
30. Maheshwari A, Mahato RI, McGregor J et al. Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol. Ther. 2 (2), 121-130 (2000).
31. Fewell JG, Matar M, Slobodkin G et al. Synthesis and application of a non-viral gene delivery system for immunogene therapy of cancer. J. Control. Release 109 (1-3), 288-298 (2005).
32. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5 (10), 791-796 (2006).
33. Diez S, Migueliz I, Tros De Ilarduya C. Targeted cationic poly (d,l-lactic-co-glycolic acid) nanoparticles for gene delivery to cultured cells. Cell Mol. Biol. Lett. 14 (2), 347-362 (2009).
34. Hallaj-Nezhadi S, Lotfipour F, Dass C. Nanoparticle-mediated interleukin-12 cancer gene therapy. J. Pharm. Pharm. Sci. 13 (3), 472-485 (2010).
35. Kaul G, Amiji M. Cellular interactions and in vitro DNA transfection studies with poly (ethylene glycol)-modified gelatin nanoparticles. J. Pharm. Sci. 94 (1), 184-198 (2005).
36. Barker SE, Grosse SM, Siapati EK et al. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br. J. Cancer 97 (2), 210-217 (2007).
37. Croce M, Meazza R, Orengo AM et al. Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clin. Cancer Res. 11 (2 Pt 1), 735-742 (2005).
38. Kasai H, Iwamoto-Tanaka N, Fukada S. DNA modifications by the mutagen glyoxal: Adduction to G and C, deamination of C and GC and GA cross-linking. Carcinogenesis 19 (8), 1459-1465 (1998).
39. Azarmi S, Huang Y, Chen H et al. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J. Pharm. Pharm. Sci. 9 (1), 124-132 (2006).
40. Truong-Le VL, Walsh SM, Schweibert E et al. Gene transfer by DNA-gelatin nanospheres. Arch. Biochem. Biophys. 361 (1), 47-56 (1999).
41. Kaul G, Amiji M. Long-circulating poly (ethylene glycol)-modified gelatin nanoparticles for intracellular delivery. Pharm. Res. 19 (7), 1061-1067 (2002).
42. Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, Langer K. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26 (15), 2723-2732 (2005).
43. Gupta AK, Gupta M, Yarwood SJ, Curtis AS. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organisation of human fibroblasts. J. Control. Release 95 (2), 197-207 (2004).